Tocilizumab and soluble interleukin-6 receptor in JAK2V617F somatic mutation and myeloproliferative neoplasm

Detalles Bibliográficos
Autores principales: Pedersen, Kasper Mønsted, Çolak, Yunus, Hasselbalch, Hans Carl, Bojesen, Stig Egil, Nordestgaard, Børge Grønne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7205745/
https://www.ncbi.nlm.nih.gov/pubmed/32395710
http://dx.doi.org/10.1016/j.eclinm.2020.100337
_version_ 1783530296533057536
author Pedersen, Kasper Mønsted
Çolak, Yunus
Hasselbalch, Hans Carl
Bojesen, Stig Egil
Nordestgaard, Børge Grønne
author_facet Pedersen, Kasper Mønsted
Çolak, Yunus
Hasselbalch, Hans Carl
Bojesen, Stig Egil
Nordestgaard, Børge Grønne
author_sort Pedersen, Kasper Mønsted
collection PubMed
description
format Online
Article
Text
id pubmed-7205745
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-72057452020-05-11 Tocilizumab and soluble interleukin-6 receptor in JAK2V617F somatic mutation and myeloproliferative neoplasm Pedersen, Kasper Mønsted Çolak, Yunus Hasselbalch, Hans Carl Bojesen, Stig Egil Nordestgaard, Børge Grønne EClinicalMedicine Letter Elsevier 2020-05-03 /pmc/articles/PMC7205745/ /pubmed/32395710 http://dx.doi.org/10.1016/j.eclinm.2020.100337 Text en © 2020 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Letter
Pedersen, Kasper Mønsted
Çolak, Yunus
Hasselbalch, Hans Carl
Bojesen, Stig Egil
Nordestgaard, Børge Grønne
Tocilizumab and soluble interleukin-6 receptor in JAK2V617F somatic mutation and myeloproliferative neoplasm
title Tocilizumab and soluble interleukin-6 receptor in JAK2V617F somatic mutation and myeloproliferative neoplasm
title_full Tocilizumab and soluble interleukin-6 receptor in JAK2V617F somatic mutation and myeloproliferative neoplasm
title_fullStr Tocilizumab and soluble interleukin-6 receptor in JAK2V617F somatic mutation and myeloproliferative neoplasm
title_full_unstemmed Tocilizumab and soluble interleukin-6 receptor in JAK2V617F somatic mutation and myeloproliferative neoplasm
title_short Tocilizumab and soluble interleukin-6 receptor in JAK2V617F somatic mutation and myeloproliferative neoplasm
title_sort tocilizumab and soluble interleukin-6 receptor in jak2v617f somatic mutation and myeloproliferative neoplasm
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7205745/
https://www.ncbi.nlm.nih.gov/pubmed/32395710
http://dx.doi.org/10.1016/j.eclinm.2020.100337
work_keys_str_mv AT pedersenkaspermønsted tocilizumabandsolubleinterleukin6receptorinjak2v617fsomaticmutationandmyeloproliferativeneoplasm
AT colakyunus tocilizumabandsolubleinterleukin6receptorinjak2v617fsomaticmutationandmyeloproliferativeneoplasm
AT hasselbalchhanscarl tocilizumabandsolubleinterleukin6receptorinjak2v617fsomaticmutationandmyeloproliferativeneoplasm
AT bojesenstigegil tocilizumabandsolubleinterleukin6receptorinjak2v617fsomaticmutationandmyeloproliferativeneoplasm
AT nordestgaardbørgegrønne tocilizumabandsolubleinterleukin6receptorinjak2v617fsomaticmutationandmyeloproliferativeneoplasm

Ejemplares similares